The Latest
FEELINGIRL Reports Outstanding Sales Performance in 2024, Driven by Seamless Shapewear Line

FEELINGIRL Reports Outstanding Sales Performance in 2024, Driven by Seamless Shapewear Line

RANCHO CUCAMONGA, Calif., Dec. 18, 2024 /PRNewswire/ — FEELINGIRL, a self-confidence-oriented brand…
  • December 18, 2024

Rokt Strengthens Executive Team with Appointment of Two New Leaders

Company Names Jacqueline Purcell as Chief Financial Officer and Claire Southey as…
  • December 18, 2024
Fliption Partners with U.S. Studio to Revolutionize Brand Content Recycling with AI for North American Expansion

Fliption Partners with U.S. Studio to Revolutionize Brand Content Recycling with AI for North American Expansion

Fliption opens New York office to strengthen collaboration with global e-commerce brands…
  • December 18, 2024
Boryung Announces Winners of the 3rd Humans In Space Challenge

Boryung Announces Winners of the 3rd Humans In Space Challenge

Paving the Way as a Global Leader in Space Healthcare – Introducing…
  • December 18, 2024

TDengine Expands Industrial Data Offerings in 2024, Achieves 2x Revenue Growth

LOS GATOS, Calif., Dec. 18, 2024 /PRNewswire/ — TDengine, the time-series database…
  • December 18, 2024

WiMi Develops FPGA-Based Digital Quantum Computer Verification Technology

BEIJING, Dec. 18, 2024 /PRNewswire/ — WiMi Hologram Cloud Inc. (NASDAQ: WiMi)…
  • December 18, 2024

DNAnexus Recognized by Frost & Sullivan for Ability to Integrate and Synchronize Diverse Clinical and Multi-omics Data

Leading cloud-based enterprise platform for precision health data empowers biopharma companies with actionable…
  • December 18, 2024

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model

In a head-to-head diet-induced obese (DIO) mouse study, ASC47 low dose combination…
  • December 18, 2024